Based on the above, our pan-cancer analysis systematically discussed the characteristics of EFHD2 from many aspects, such as expression, survival prognosis, gene mutation, tumor immune microenvironment, and drug resistance. This evidence concerns the gene EFHD2 and neoplasm.